Author

Yongtao Li

Observed names: Li, Yongtao, YongTao Li

Institutions: Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University

Observed institutions: Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University

ORCID: 0000-0001-9297-1258

Observed ORCID: 0000-0001-9297-1258

OpenAlex ID: A5000409380

HSPA8 Is a New Biomarker of Triple Negative Breast Cancer Related to Prognosis and Immune Infiltration

2022 · Bicheng Ying, Wenting Xu, et al. · Disease Markers · 34

Response and prognosis to neoadjuvant chemotherapy in women early breast cancer of HER2-low status

2025 · Yongtao Li, Tangnuer Buerliesi, et al. · Frontiers in Oncology · 2

Analysis code and data for: Integrative ceRNA Network Analysis Identifies Candidate Regulatory Modules Associated with Chemoresistance in Triple-Negative Breast Cancer

2026 · YongTao Li · ScienceDB

Beyond chaperoning: HSPA8 modulates alternative splicing of PPP2R2D to drive apoptotic evasion and macrophage-associated immune microenvironment remodeling in triple-negative breast cancer

2026 · Wenting Xu, Qingwen Zheng, et al. · Frontiers in Oncology

Integrative ceRNA Network Analysis Reveals Coordinated Immune Evasion, Angiogenesis, and Transcriptional Reprogramming in Chemoresistant Triple- Negative Breast Cancer

2026 · Yongtao Li, Miaomiao Zhang, et al. · Research Square

HSPA8 globally modulates transcriptome profile and PI3K/AKT signaling pathway to facilitate malignant progression phenotypes of triple-negative breast cancer

2026 · Wenting Xu, Yongtao Li, et al. · Science Progress

Works count: 8

Citation count: 36

H-index: 2

I10-index: 1